Adenoviral Conjunctivitis

Okogen is a biotechnology company focused on developing therapeutics to help patients with ophthalmic diseases. The lead candidate is OKG-0301, a potent, broad-spectrum antiviral that functions intracellularly to inhibit viral replication and reduce inflammation. These mechanisms of action provide opportunity to address adenoviral infections of the eye as well as other classes of viruses that are active in the ocular space. Approximately 25 million individuals get adenoviral ocular infections annually, globally. There are no therapeutics available to treat these patients and care is primarily supportive. Okogen is initiating a phase 2 clinical trial to assess the safety and efficacy of OKG-0301, with top line results expected in early 2020.


Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.